Oppenheimer Increases Protara Therapeutics (NASDAQ:TARA) Price Target to $30.00

Protara Therapeutics (NASDAQ:TARA) had its target price raised by Oppenheimer from $26.00 to $30.00 in a research report sent to investors on Monday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Separately, HC Wainwright restated a buy rating and set a $23.00 price objective on shares of Protara Therapeutics in a report on Monday, April 8th.

Protara Therapeutics Price Performance

Shares of TARA opened at $3.05 on Monday. The company has a market capitalization of $34.86 million, a PE ratio of -0.85 and a beta of 1.71. Protara Therapeutics has a one year low of $1.04 and a one year high of $5.24. The company’s fifty day moving average price is $3.76 and its 200 day moving average price is $2.47.

Protara Therapeutics (NASDAQ:TARA) last announced its earnings results on Wednesday, March 13th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.13. Analysts anticipate that Protara Therapeutics will post -3.56 earnings per share for the current year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.